eIF4E1B Activators
Eukaryotic translation initiation factor 4E family member 1B (EIF4E1B) activators are a class of compounds that influence the eukaryotic initiation phase of protein synthesis either through direct interaction with EIF4E1B or by modulating the signaling pathways that govern its activity. For instance, the cap analog 7-Methylguanosine 5'-triphosphate directly enhances the activity of EIF4E1B by mimicking the natural mRNA cap, facilitating EIF4E1B's role in the recruitment of ribosomes for translation initiation. Substances like insulin and rapamycin modulate the mTORpathway, which plays a pivotal role in the regulation of EIF4E1B through its interaction with 4E-BP proteins. When insulin activates the PI3K/Akt/mTOR pathway, it leads to the phosphorylation and subsequent release of EIF4E1B from inhibitory 4E-BP proteins, thereby increasing EIF4E1B's availability to initiate translation. Conversely, rapamycin inhibits mTORC1, leading to less phosphorylated 4E-BP and a resultant increase in free EIF4E1B to participate in translation initiation.
Other compounds such as Paclitaxel and LY294002 indirectly influence EIF4E1B activity through their effects on the mTOR signaling pathway. Paclitaxel, by stabilizing microtubules, can activate mTOR and promote EIF4E1B activity. LY294002, though primarily a PI3K inhibitor, can induce compensatory feedback that activates mTORC1, thus enhancing EIF4E1B function. Similarly, U0126 and Triciribine, although they are inhibitors of MEK1/2 and Akt respectively, can trigger feedback loops that ultimately promote mTORC1 signaling and increase EIF4E1B activity. Resveratrol, by activating sirtuins, influences the PI3K/Akt/mTOR axis and can lead to the enhancement of EIF4E1B activity. Metformin, through AMPK activation, inhibits mTORC1 but can lead to reduced phosphorylation of 4E-BPs, thus raising the levels of active EIF4E1B.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
Insulin activates the PI3K/Akt/mTOR pathway, which in turn can lead to the phosphorylation of 4E-BPs. Phosphorylated 4E-BPs release EIF4E1B, thereby enhancing its availability to initiate translation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to mTORC1 and inhibits its activity. Inhibition of mTORC1 leads to reduced phosphorylation of 4E-BPs, which can result in a greater availability of EIF4E1B for cap-dependent translation initiation by preventing the sequestration of EIF4E1B. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and can activate the mTOR pathway indirectly. Activation of mTOR can enhance the phosphorylation state of 4E-BP1, promoting the release and activation of EIF4E1B for translation initiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This chemical is a PI3K inhibitor that affects the PI3K/Akt/mTOR pathway. By inhibiting PI3K, it leads to the activation of feedback loops that can, paradoxically, result in the activation of mTORC1 signaling under certain conditions, thereby potentially increasing EIF4E1B activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which can lead to a compensatory activation of the PI3K/Akt/mTOR pathway. This increase in mTOR signaling can enhance the release and activity of EIF4E1B by phosphorylating 4E-BPs. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an Akt inhibitor that can trigger compensatory feedback loops leading to mTORC1 activation and subsequent phosphorylation of 4E-BPs, which increases the availability of EIF4E1B for translation initiation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol activates sirtuins, which can influence the PI3K/Akt/mTOR pathway. By modulating this pathway, resveratrol can indirectly enhance the activity of EIF4E1B through the mTOR-mediated control of 4E-BP phosphorylation. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Metformin activates AMP-activated protein kinase (AMPK), which can inhibit mTORC1, leading to reduced phosphorylation of 4E-BPs and thus increased availability of EIF4E1B for translational initiation. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
Dactolisib is a dual PI3K/mTOR inhibitor that, by inhibiting these kinases, can activate downstream feedback loops that lead to the activation of mTORC1 signaling, potentially enhancing the activity of EIF4E1B through 4E-BP1 phosphorylation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus specifically inhibits mTORC1 similarly to rapamycin, and by doing so, it can lead to a compensatory increase in PI3K signaling. This can result in enhanced phosphorylation of 4E-BPs and increased activity of EIF4E1B. | ||||||